Journal
CLINICAL INFECTIOUS DISEASES
Volume 37, Issue 12, Pages 1668-1677Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/379775
Keywords
-
Categories
Ask authors/readers for more resources
Respiratory syncytial virus ( RSV) and human parainfluenza viruses ( hPIVs) are leading causes of viral lower respiratory tract illness in children and in high- risk adult populations. Despite decades of research, licensed vaccines for RSV and hPIVs do not exist. Recently, however, genetically engineered live attenuated RSV and hPIV candidate vaccines have been generated, several of which are already being evaluated in clinical trials. Recombinant technology allows candidate vaccines to be fine-tuned in response to clinical data, which should hasten the development of vaccines against these important respiratory pathogens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available